Page 135 - Contributed Paper Session (CPS) - Volume 1
P. 135

CPS1201 M. Iftakhar Alam et al.


                         Combined criteria for dose optimisation in early
                                        phase clinical trials
                                       1
                                                          2
                                                                            2
                       M. Iftakhar Alam , D. Stephen Coad  , Barbara Bogacka
            1 Institute of Statistical Research and Training, University of Dhaka, Dhaka 1000, Bangladesh
            2 School of Mathematical Sciences, Queen Mary University of London, London E1 4NS, U.K.

            Abstract
            The paper aims to investigate whether any bridge is possible between so-
            called best intention and D-optimum designs. It introduces combined criteria
            for dose optimisation in seamless phase I/II adaptive clinical trials. Each of the
            optimality criteria considers efficacy and toxicity as endpoints and is based on
            the probability of a successful outcome and on the determinant of the Fisher
            information matrix for estimation of the doseresponse parameters. In addition,
            one of the criteria incorporates penalties for choosing a toxic or inefficacious
            dose. Starting with the lowest dose, the adaptive design selects the dose for
            each subsequent cohort that maximises the respective defined criterion. The
            methodology is illustrated with a dose-response model that assumes trinomial
            responses. Simulation studies show that the method is capable of identifying
            the optimal dose accurately without exposing many patients to toxic doses.

            Keywords
            Adaptive design; Continuation ratio model; D-optimum design; Penalty
            function; Phase I/II trial.

            1.  Introduction
                Different  methods  are  being  developed  to  increase  the  popularity  of
            seamless phase I/II clinical trials. There are designs proposed by  Thall and
            Russell (1998), Thall and Cook (2004) and Zhang et al. (2006). These designs
            have the intention of allocating the best dose to the cohort of patients based
            on the current knowledge and are known as the “best intention designs”. They
            may lead to poor learning of the dose-response relationship. In contrast, there
            are methods which rely on optimal design criteria for estimation of model
            parameters. Heise and Myers (1996) constructed the D-optimal design using
            the  Gumbel  model  for  bivariate  binary  data.  Fan  and  Chaloner  (2004)
            described the D-optimal design for trinomial responses using a continuation
            ratio  model.  Dragalin  and  Fedorov  (2006)  considered  binary  outcomes  for
            each endpoint and used either Gumbel bivariate binary logistic regression or
            the Cox bivariate binary model.
                This paper investigates whether any trade-off between the best intention
            designs taking care of individual ethics and D-optimal designs focusing more
            on collective ethics is possible. The underlying idea is to develop a design that


                                                               124 | I S I   W S C   2 0 1 9
   130   131   132   133   134   135   136   137   138   139   140